Security key
98937L105
Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (ZBIO)
CUSIP: 98937L105
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 34,055,191
- Total 13F value
- $329,977,952
- Share change
- +1,589,258
- SEC-reported price per share
- $9.69
- Number of holders
- 72
- Value change
- +$15,611,752
- Number of buys
- 44
- Number of sells
- 16
- Shares outstanding
- 63,278,585
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
72
Top holders
10
ZBIO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Zenas BioPharma, Inc. SEC filings
Zenas BioPharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98937L105
Recent filing periods:
Ownership snapshot
Top reported holders of ZBIO - Zenas BioPharma, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
SR ONE CAPITAL MANAGEMENT...
Disclosed value leader
Enavate Sciences GP, LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13F
3/4/5
Lead comparable stake: 7.8%
Showing 1-6 of 15 holder rows.
Quick read
SR ONE CAPITAL MANAGEMENT, LP leads the comparable SEC ownership view at 7.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens SR ONE CAPITAL MANAGEMENT, LP's linked filing trail.
Comparable ownership
Top 5
SR ONE CAPITAL MANAGEMENT, LP
7.8%
Enavate Sciences GP, LLC
5.9%
FMR LLC
4.5%
NEA Management Company, LLC
4.1%
Novo Holdings A/S
3.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP |
13F
Company
|
7.8%
|
$38,801,158
4,911,539 shares
|
— | 31 Mar 2025 |
| Enavate Sciences GP, LLC |
3/4/5
13F
10%+ Owner · Company
|
5.9%
from 13F
|
$63,943,103
3,761,359 shares
|
— | 16 Sep 2024 |
| FMR LLC |
13F
Company
|
4.5%
|
$22,533,732
2,852,371 shares
|
— | 31 Mar 2025 |
| NEA Management Company, LLC |
13F
Company
|
4.1%
|
$20,650,189
2,613,948 shares
|
— | 31 Mar 2025 |
| Novo Holdings A/S |
13F
Company
|
3.5%
|
$17,498,239
2,214,967 shares
|
— | 31 Mar 2025 |
| Fairmount Funds Management LLC |
13F
Company
|
3%
|
$14,953,167
1,892,806 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
72
Shares
34,055,191
Rows available
72
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
67
Q2 2025 holders
72
Holder diff
5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend